Journal article
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
Abstract
BACKGROUND: Recombinant factors VIII and IX Fc (rFVIIIFc/rFIXFc) were the only available extended half-life (EHL) products in Canada during 2016 to 2018.
OBJECTIVES: To evaluate if patient-reported outcome measures (PROMs) improved in Canadian persons with hemophilia who switched from standard half-life (SHL) to EHL products (rFVIIIFc/rFIXFc).
Authors
Sun H; Yang M; Poon M; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M
Journal
Research and Practice in Thrombosis and Haemostasis, Vol. 5, No. 7,
Publisher
Elsevier
Publication Date
October 2021
DOI
10.1002/rth2.12601
ISSN
2475-0379